Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 248

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Open access
Combe, Bernard, Kivitz, Alan, Tanaka, Yoshiya, van der Heijde, Désirée, Simon, J Abraham, Baraf, Herbert S B, Kumar, Uma, Matzkies, Franziska, Bartok, Beatrix, Ye, Lei, Guo, Ying, Tasset, Chantal, Sundy, John S, Jahreis, Angelika, Genovese, Mark C, Mozaffarian, Neelufar, Landewé, Robert B M, Bae, Sang-Cheol, Keystone, Edward C, Nash, Peter · 2021 · Annals of the Rheumatic Diseases

Abstract

OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). METHODS: This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial evaluated once-daily oral filgotinib in patients with RA randomised 3:3:2:3 to filgotinib 200 mg (FIL200) or filgotinib 100 mg (FIL100), subcutaneous adalimumab 40 mg biweekly, or placebo (through week 24), all with stable weekly background MTX. The primary endpoint was the proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Additional efficacy outcomes were assessed sequentially. Safety was assessed from adverse events and laboratory abnormalities. RESULTS: The proportion of patients (n=1755 randomised and treated) achieving ACR20 at week 12 was significantly higher for FIL200 (76.6%) and FIL100 (69.8%) versus placebo (49.9%; treatment difference (95% CI), 26.7% (20.6% to 32.8%) and 19.9% (13.6% to 26.2%), respectively; both p<0.001). Filgotinib was superior to placebo in key secondary endpoints assessing RA signs and symptoms, physical function and structural damage. FIL200 was non-inferior to adalimumab in terms of Disease Activity Score in 28 joints with C reactive protein ≤3.2 at week 12 (p<0.001); FIL100 did not achieve non-inferiority. Adverse events and laboratory abnormalities were comparable among active treatment arms. CONCLUSIONS: Filgotinib improved RA signs and symptoms, improved physical function, inhibited radiographic progression and was well tolerated in patients with RA with inadequate response to MTX. FIL200 was non-inferior to adalimumab. TRIAL REGISTRATION NUMBER: NCT02889796.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2020-219214

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 248

Metadata

Authors
Combe, B., Kivitz, A., Tanaka, Y., van der Heijde, D., Simon, J. A., Baraf, H. S. B., Kumar, U., Matzkies, F., Bartok, B., Ye, L., Guo, Y., Tasset, C., Sundy, J. S., Jahreis, A., Genovese, M. C., Mozaffarian, N., Landewé, R. B. M., Bae, S.-C., Keystone, E. C., & Nash, P.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2021-07
Volume
80
Issue
7
Pages
848-858
ISSN
0003-4967 (ISSN-L)
OpenAlex
W3124339251
Cited by
248
References
1
FWCI
27.17
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2020-219214
The paper
Combe, B., Kivitz, A., Tanaka, Y., van der Heijde, D., Simon, J. A., Baraf, H. S. B., Kumar, U., Matzkies, F., Bartok, B., Ye, L., Guo, Y., Tasset, C., Sundy, J. S., Jahreis, A., Genovese, M. C., Mozaffarian, N., Landewé, R. B. M., Bae, S.-C., Keystone, E. C., & Nash, P. (2021). Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2020-219214

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.